Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Luis de la Cruz‐Merino et al.|New England Journal of Medicine|2014Cited by 2k
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced <i>BRAF</i>-mutated melanoma.James Larkin, Antoni Ribas, Yibing Yan et al.|Journal of Clinical Oncology|2015Cited by 48
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Paolo A. Ascierto, Antoni Ribas, Grant A. McArthur et al.|Journal of Translational Medicine|2015Cited by 31
Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).Brigitte Dréno, Antoni Ribas, Karen Bartley et al.|Journal of Clinical Oncology|2015Cited by 7
Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)Grant A. McArthur, Brigitte Dréno, Paolo A. Ascierto et al.|Annals of Oncology|2014Cited by 3